MGI Wins Biotechnology Innovation Enterprise Award in the Greater Bay Area
On 16 October 2019, Shenzhen MGI Technology Co., Ltd. received the Biotechnology Innovation Enterprise Award of the Guangdong–Hong Kong–Macao Greater Bay Area.
The event was hosted by the China Venture Industry Research Institute and KPMG China, with Guangdong Medical Valley serving as co-organiser. The Greater Bay Area Biotechnology Innovation and Development Summit was held on the same day.
Highlighting Innovation in the Greater Bay Area
During the event, organisers also released the “Top 50 Innovation Report of Biotech Enterprises in the Guangdong–Hong Kong–Macao Greater Bay Area.”
The report highlights the latest achievements of biotechnology innovation enterprises across the region and analyses emerging industry trends and development opportunities.
Key trends identified in the report include:
- The continued clustering and growth of the biomedical industry
- The expansion of large-scale biotechnology services
- Regional collaboration and differentiated industrial development
- The emergence of large-scale medical IoT ecosystems enabled by 5G technology
- The deepening integration of artificial intelligence and biomedicine
Driving Innovation in Gene Sequencing
Within this rapidly evolving industry landscape, MGI remains committed to advancing genomic technology and supporting innovation in the life sciences sector.
The company provides a comprehensive range of gene sequencing platforms designed to support diverse research and clinical applications, helping customers address a wide variety of sequencing needs.
Recently, MGI delivered one of the world’s most powerful sequencing instruments, the DNBSEQ-T7, often referred to as a “super life computer”. The platform delivers ultra-high sequencing throughput and strong cost efficiency.
This innovation helps strengthen the competitiveness of China’s gene sequencing industry by overcoming technical barriers and contributing to the continued growth of the global genomics sector.
